MED1-mediated increase in cell proliferation and migration is inhibited upon miR-191 downregulation, suggesting the presence of a MED1/ER-α/miR-191 oncogenic axis that could serve as an effective target for breast cancer therapy. This evidence concerns the gene ESR1 and breast carcinoma.